HOME ABOUT US TECHNOLOGY PRODUCTS CONTACT US  
 
       
 
 

News
   
  About Us
  Career Opportunities
  Directions
  News
     


May 12, 2009
BioHelix Corporation has obtained a Cooperative Agreement and a Phase II SBIR Award from the NIAID for the development of diagnostic assays for CT/NG and HIV.


BioHelix announced today that it has entered into a multi-year Cooperative Agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to develop a simple and cost-effective IsoAmp® Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) test for use at STD clinics. In addition, after the successful completion of a Phase 1 Small Business Innovative Research (SBIR) HIV grant, the company has also received a three-year, Phase II Advanced Technology SBIR award from the NIAID for the development of a low-cost HIV molecular diagnostic test based on BioHelix's "instrument-free" IsoAmp® platform.

 
<<Back to News
         
Privacy, Limitation, Warranty, Disclaimer